Suptavumab

Suptavumab
Monoclonal antibody
Type	?
Source	Human
Target	respiratory syncytial virus fusion protein
Clinical data
Other names	REGN2222
ATC code	none;
Identifiers
CAS Number	1629615-23-1;
ChemSpider	none;
UNII	A0ZE931055;
KEGG	D10991;
Chemical and physical data
Formula	C6502H10038N1726O2020S42
Molar mass	146054.41 g·mol−1

Suptavumab (INN;^[1] development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus.

This experimental drug candidate was being developed by Regeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials.^[2]^[3]

References

^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.
^ "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[WHOList115-1] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).

[2] Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.

[3] "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.

[1]

[2]

[3]